- Related Products
MedEx answers any queries you might have regarding Sutent-50 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Tragically, both gastrointestinal stromal tumors and disseminated kidney cancer are not uncommon. The rate of morbidity among the patients from CIS countries is very high. But that’s not the point. It’s not always possible to successfully fight these diseases with the help of imatinib or cytokines. Patients often become intolerant to one or several components of the above-mentioned drugs. In this case, specific treatment becomes impossible.
In this case, you need the drug that has minimal intolerance and can successfully prevent the disease, and this is an anti-cancer drug Sutent. The drug blocks the action of some kinases, responsible for the growth of tumor. Therfore, Sutent 50 mg acts at a microcellular level. It is especially important if there are metastases. In this case, you get the chance to fight the illness and achieve stable remission.
Sutent is prescribed for the treatment of adult patients with the following types of cancer:
Gastrointestinal stromal tumors that can not be surgically removed or spread to other parts of the body.
Metastatic renal cell carcinoma.
Tumors of the pancreas of the neuroendocrine type.
Dosage of Sutent 50 mg
The recommended dose is 50 mg a day for 4 weeks with the consequent 2-week break (4/2 mode). Thus, a full treatment cycle takes 6 weeks.
Depending on the individual tolerance, the dose of Sutent can be reduced or increased by 12.5 mg. The daily dose must not exceed 87.5 mg. The minimum dose is 25 mg a day.
Way of use
Sutent 50 mg can be taken irrespective of the mealtime. If you missed a pill, don’t make up for the skipped dose. Just take the usual drug dose next day.
Interaction with the other drugs
There are a number of drugs that can reduce and decreased the concentration of sunitinib in blood plasma.
The first type of compatible drugs includes CYP3A4 inhibitors (itraconazole, ritonavir, erythromycin, clarithromycin or grapefruit juice).
The drugs reducing the concentration of Sunitinib in blood plasm, include CYP3A4 inductors (rifampicin, dexamethasone, carbamazepine, phenobarbital or St. John’s wort).
Sutent is a modern drug used in oncology for the treatment of malignant tumors of a certain localization and type. The mechanism of action of the drug is associated with the suppression of the activity of enzymes involved in the growth and proliferation of tumor cells. It oppresses the formation of the vascular network that feeds the primary tumor area. Therapy with the drug Sutent can stop the growth of the tumor and slow the process of metastasis.
Clinical studies have shown that the use of Sutent can stop tumor growth and metastasis, increase the life expectancy and well-being of patients.